ଉପାଡାସିଟିନିବ

ଉପାଡାସିଟିନିବ
Clinical data
Trade names	Rinvoq
Synonyms	ABT-494
AHFS/Drugs.com	monograph
MedlinePlus	a619051
data	EU EMA: yes; US DailyMed: Upadacitinib;
Pregnancy; category	AU: D ; US: N (Not classified yet) ; Not recommended;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Pharmacokinetic data
Protein binding	52%
Metabolism	Hepatic (CYP3A major, CYP2D6 minor)
Metabolites	M4, an acyl glucuronide
Elimination half-life	9–14 (6–15) hours
Excretion	Mainly unchanged in feces (38%) and urine (24%)
Identifiers
	IUPAC name (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide;
Chemical and physical data
Formula	C17H19F3N6O
Molar mass	୩୮୦.୩୮ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F;
	InChI InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1 ; Key:WYQFJHHDOKWSHR-MNOVXSKESA-N ;

ଉପାଡାସିଟିନିବ, ଏକ ବେପାର ନାମ ରିନାଭୋକ, ବ୍ରାଣ୍ଡ ହେଉଛି ଏକ ଔଷଧ ଯାହା ମଧ୍ୟମରୁ ଗୁରୁତର ଧରଣର ରିଉମାଟଏଡ ଆର୍ଥ୍ରାଇଟିସର (RA) ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ଯେଉଁଠାରେ ମେଟୋଟ୍ରେକ୍ସେଟ୍ ଯଥେଷ୍ଟ ପ୍ରଭାବଶାଳୀ ହୁଏନି ।^[୭] ଏହି ରୋଗରେ ପାରମ୍ପରିକ ଔଷଧ ସହିତ ଏକତ୍ର ବ୍ୟବହୃତ ହୋଇପାରେ କିନ୍ତୁ ଇମ୍ୟୁନୋସପ୍ରେସିଭ୍ ଏଜେଣ୍ଟ ସହିତ ବ୍ୟବହାର କରିବା ସୁପାରିଶ କରାଯାଏ ନାହିଁ ।^[୭] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୭]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଉର୍ଦ୍ଧ୍ୱ ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ ଯେପରିକି ଶର୍ଦ୍ଦି, ଅଇ, କାଶ ଏବଂ ଜ୍ୱର ହୋଇପାରେ ।^[୮] ^[୭] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଗମ୍ଭୀର ସଂକ୍ରମଣ, ରକ୍ତ ଜମାଟ ବାନ୍ଧିବା ଏବଂ କର୍କଟ ରୋଗ ହୋଇପାରେ । ^[୭] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି କରିପାରେ ।^[୭] ସକ୍ରିୟ ଯକ୍ଷ୍ମା ରୋଗୀଙ୍କ କ୍ଷେତ୍ରରେ ବ୍ୟବହାର କରିବାକୁ ସୁପାରିଶ କରାଯାଏ ନାହିଁ। ^[୯] ଜାନୁସ କାଇନେଜ ନାମକ ଏନଜାଇମର କାର୍ଯ୍ୟକୁ ଅବରୋଧ କରି ଉପାଡାସିଟିନିବ କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ଯାହାଦ୍ୱାରା ପ୍ରଦାହ କମିଯାଏ ।^[୭] ^[୮]

୨୦୧୯ ମସିହାରେ ୟୁରୋପ ଏବଂ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଉପାଡାସିଟିନିବକୁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୭] ^[୮] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ଔଷଧର ମୁଲ୍ଲ୍ୟ ୨୦୧୯ ମସିହାରେ ୧୮୦୦୦ ଡଲାର ଥିଲା । ୨୦୨୧ସୁଦ୍ଧା ଯୁକ୍ତରାଜ୍ୟରେ ଏହାର ବର୍ଷକୁ ମୂଲ୍ୟ ପ୍ରାୟ ୧୦,୫୦୦ ପାଉଣ୍ଡ ଥିଲା ।^[୧୦] ^[୧୧] ^[୯]

ଆଧାର[ସମ୍ପାଦନା]

↑ ^୧.୦ ^୧.୧ "Upadacitinib (Rinvoq) Use During Pregnancy". Drugs.com. 23 September 2019. Archived from the original on 18 March 2020. Retrieved 17 March 2020.
↑ "Rinvoq EPAR". European Medicines Agency (EMA). 16 October 2019. Archived from the original on 20 October 2020. Retrieved 29 April 2020.
↑ "Rinvoq 15 mg prolonged-release tablets - Summary of Product Characteristics (SmPC)". (emc). 1 March 2020. Archived from the original on 27 August 2021. Retrieved 22 August 2020.
↑ "Rinvoq- upadacitinib tablet, extended release". DailyMed. 1 March 2020. Archived from the original on 27 August 2021. Retrieved 29 April 2020.
↑ ^୫.୦ ^୫.୧ Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA (December 2016). "Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Participants with Rheumatoid Arthritis". Clinical Pharmacokinetics. 55 (12): 1547–1558. doi:10.1007/s40262-016-0419-y. PMID 27272171. S2CID 39036534.
↑ ^୬.୦ ^୬.୧ "Rinvoq: EPAR – Public assessment report" (PDF). European Medicines Agency. 2020-03-05. Archived (PDF) from the original on 2020-07-21. Retrieved 2021-06-05.
↑ ^୭.୦ ^୭.୧ ^୭.୨ ^୭.୩ ^୭.୪ ^୭.୫ ^୭.୬ ^୭.୭ "Upadacitinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 August 2021. Retrieved 13 September 2021.
↑ ^୮.୦ ^୮.୧ ^୮.୨ "Rinvoq". Archived from the original on 20 October 2020. Retrieved 13 September 2021.
↑ ^୯.୦ ^୯.୧ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1169. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ Pharmacoeconomic Review Report: Upadacitinib (Rinvoq): (AbbVie): Indication: For the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. Canadian Agency for Drugs and Technologies in Health. 2020. Archived from the original on 23 September 2021. Retrieved 13 September 2021.
↑ "Rinvoq Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 16 January 2021. Retrieved 13 September 2021.

[Drugs.com_pregnancy-1] ୧.୦ ^୧.୧ "Upadacitinib (Rinvoq) Use During Pregnancy". Drugs.com. 23 September 2019. Archived from the original on 18 March 2020. Retrieved 17 March 2020.

[Rinvoq_EPAR-2] "Rinvoq EPAR". European Medicines Agency (EMA). 16 October 2019. Archived from the original on 20 October 2020. Retrieved 29 April 2020.

[3] "Rinvoq 15 mg prolonged-release tablets - Summary of Product Characteristics (SmPC)". (emc). 1 March 2020. Archived from the original on 27 August 2021. Retrieved 22 August 2020.

[Rinvoq_FDA_label-4] "Rinvoq- upadacitinib tablet, extended release". DailyMed. 1 March 2020. Archived from the original on 27 August 2021. Retrieved 29 April 2020.

[Eslam-5] ୫.୦ ^୫.୧ Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA (December 2016). "Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Participants with Rheumatoid Arthritis". Clinical Pharmacokinetics. 55 (12): 1547–1558. doi:10.1007/s40262-016-0419-y. PMID 27272171. S2CID 39036534.

[AssessmentReport-6] ୬.୦ ^୬.୧ "Rinvoq: EPAR – Public assessment report" (PDF). European Medicines Agency. 2020-03-05. Archived (PDF) from the original on 2020-07-21. Retrieved 2021-06-05.

[AHFS2021-7] ୭.୦ ^୭.୧ ^୭.୨ ^୭.୩ ^୭.୪ ^୭.୫ ^୭.୬ ^୭.୭ "Upadacitinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 August 2021. Retrieved 13 September 2021.

[EPAR2021-8] ୮.୦ ^୮.୧ ^୮.୨ "Rinvoq". Archived from the original on 20 October 2020. Retrieved 13 September 2021.

[BNF80-9] ୯.୦ ^୯.୧ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1169. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[10] Pharmacoeconomic Review Report: Upadacitinib (Rinvoq): (AbbVie): Indication: For the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. Canadian Agency for Drugs and Technologies in Health. 2020. Archived from the original on 23 September 2021. Retrieved 13 September 2021.

[11] "Rinvoq Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 16 January 2021. Retrieved 13 September 2021.

[୧]

[୩]

[୪]

[୨]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]

[୧୧]